Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
19/10/2026 06:03
BRIEF-Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830 Oct 19 (Reuters) - Zealand Pharma A/S ZELA.CO:
ZEALAND PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE MULTIPLE ASCENDING DOSE PART OF PHASE 1 TRIAL WITH KV1.3 ION CHANNEL BLOCKER ZP9830
MULTIPLE DOSES OF ZP9830 WELL TOLERATED WITH NO SERIOUS OR DOSE-LIMITING SAFETY FINDINGS
ALL TREATMENT-EMERGENT ADVERSE EVENTS FOR ZP9830 WERE NON-SERIOUS AND MILD
Source text: ID:nGNE9vbhTD
Further company coverage: ZELA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)